In this optimized model, we found the combined treatment effectively increased the expression of KLF-2 and ZO-1, attenuated the expression of NF-kB, which improved the inflammatory reaction, stabilized the neovascularization, and rapidly decreased the hematoma volume, resulting in the lowest mortality when comparing to other treatment groups. This evidence concerns the gene NFKB1 and hematoma.